Perrigo Company plc Available-for-sale Equity Securities, Amortized Cost Basis
Perrigo Company plc (PRGO) had Available-for-sale Equity Securities, Amortized Cost Basis of $15.50 million as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis · last filed 2018-03-01
- 2017-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $15.50M.
- 2016-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $16.50M.
- 2016-10-01: Available-for-sale Equity Securities, Amortized Cost Basis $20.10M.
- 2016-07-02: Available-for-sale Equity Securities, Amortized Cost Basis $20.20M.
| Period end | Available-for-sale Equity Securities, Amortized Cost Basis | Available-for-sale Equity Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-12-31 | $15.50M 10-K · filed 2018-03-01 | |
| 2016-12-31 | $16.50M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $20.10M 10-Q/A · filed 2017-05-23 | |
| 2016-07-02 | $20.20M 10-Q/A · filed 2017-05-22 | |
| 2016-04-02 | $21.90M 10-Q/A · filed 2017-05-22 | |
| 2015-12-31 | $6.40M 10-K · filed 2018-03-01 | |
| 2015-09-26 | $17.10M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $17.10M 10-K · filed 2017-05-22 | |
| 2015-03-28 | $17.10M 10-Q · filed 2015-04-29 | |
| 2014-09-27 | $17.10M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $17.10M 10-KT · filed 2016-02-25 | |
| 2013-12-28 | $17.10M 10-Q · filed 2015-02-05 | $90.30M 10-Q · filed 2014-02-06 |
| 2013-06-29 | $0.00 10-K · filed 2014-08-14 | |
| 2012-06-30 | $7.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |